Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in children.
The post Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma appeared first on MedCity News.
